Marija Pfeifer
Overview
Explore the profile of Marija Pfeifer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
997
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Valassi E, Franz H, Brue T, Feelders R, Netea-Maier R, Tsagarakis S, et al.
Eur J Endocrinol
. 2018 Feb;
178(4):399-409.
PMID: 29440375
Background: Surgery is the definitive treatment of Cushing's syndrome (CS) but medications may also be used as a first-line therapy. Whether preoperative medical treatment (PMT) affects postoperative outcome remains controversial....
12.
Castinetti F, Maia A, Peczkowska M, Barontini M, Hasse-Lazar K, Links T, et al.
Endocr Relat Cancer
. 2017 Jun;
24(8):L63-L67.
PMID: 28649091
No abstract available.
13.
Valassi E, Franz H, Brue T, Feelders R, Netea-Maier R, Tsagarakis S, et al.
Eur J Endocrinol
. 2017 Apr;
176(5):613-624.
PMID: 28377460
Objective: To evaluate which tests are performed to diagnose hypercortisolism in patients included in the European Registry on Cushing's syndrome (ERCUSYN), and to examine if their use differs from the...
14.
Strasburger C, Vanuga P, Payer J, Pfeifer M, Popovic V, Bajnok L, et al.
Eur J Endocrinol
. 2016 Dec;
176(3):283-294.
PMID: 27932411
Objective: Growth hormone (GH) replacement therapy currently requires daily injections, which may cause distress and low compliance. C-terminal peptide (CTP)-modified growth hormone (MOD-4023) is being developed as a once-weekly dosing...
15.
Rep S, Lezaic L, Kocjan T, Pfeifer M, Jensterle Sever M, Simoncic U, et al.
Radiol Oncol
. 2016 Feb;
49(4):327-33.
PMID: 26834518
Background: Parathyroid adenomas, the most common cause of primary hyperparathyroidism, are benign tumours which autonomously produce and secrete parathyroid hormone. [(18)F]-fluorocholine (FCH), PET marker of cellular proliferation, was recently demonstrated...
16.
Jezovnik M, Jensterle Sever M, Janez A, Pfeifer M, Spirkoska A, Kravos N, et al.
Int Angiol
. 2015 May;
35(5):446-54.
PMID: 26017763
Background: The prognostic importance of preclinical markers of atherosclerosis and their interrelationship are inconclusive. In this study interrelationship between different methods investigating endothelial function and intima media thickness (IMT) was...
17.
Rochette C, Jullien N, Saveanu A, Caldagues E, Bergada I, Braslavsky D, et al.
PLoS One
. 2015 May;
10(5):e0126648.
PMID: 25955177
LHX4 is a LIM homeodomain transcription factor involved in the early steps of pituitary ontogenesis. To date, 8 heterozygous LHX4 mutations have been reported as responsible of combined pituitary hormone...
18.
Jensterle M, Kravos N, Pfeifer M, Kocjan T, Janez A
Hormones (Athens)
. 2015 Apr;
14(1):81-90.
PMID: 25885106
Objective: The long-acting glucagon-like peptide 1 receptor agonist liraglutide is linked to progressive and sustained weight loss in obese people with diabetes. However, its efficacy and safety in women with...
19.
Jensterle M, Kocjan T, Kravos N, Pfeifer M, Janez A
Endocr Res
. 2014 Oct;
40(3):133-8.
PMID: 25330463
Aim: Glucagon-like peptide 1 receptor agonists (GLP-1 RA) stimulate satiety leading to reductions in food intake and body weight. The effects of long- acting GLP-1 RA liraglutide on eating behavior...
20.
Conway G, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale H, Franks S, Gambineri A, et al.
Eur J Endocrinol
. 2014 Jul;
171(4):489-98.
PMID: 25049203
Background: There is evidence for differences between endocrinologists and other specialists in their approach to diagnosis and management of the polycystic ovary syndrome (PCOS). Objective: A mailed survey consisting of...